Obesity: latest news - GoINPHARMA
Tuesday, 11 December 2018 - 23:37

Obesity

United States try to react to obesity’s rise with new rule

The New York City Health Department last Friday imposed food industry to reduce sugar content in industrially-processed food. Specifically, the new order prescribes to reduce sugar by 20% in all industrially-processed products and by 40% in all fizzy drinks. The…

Link between obesity and cognitive capacities discovered

Over the last few years, various scientific articles have tried to detect a link between obesity and cognitive capacities. The studies followed statistical observation suggesting that cognitive capacities are lower in obese babies than in non-obese ones.  A report published…

Novo Nordisk discloses ambitious development plans for obesity drugs

Denmark-based Novo Nordisk yesterday announced at a meeting with investors that it plans to conduct a Phase-III PIONEER clinical trial with as many as 4,500 patients with obesity, assessing the investigational drug semaglutide (NN9536). The decision reflects the highly positive…

Successful IPO for Rhythm Pharmaceuticals: +52%

The young, Boston-based Rhythm Pharmaceuticals has celebrated his first days as a listed company (Nasdaq) with an exploit taking its capitalization to $706m. The IPO was submitted on October 6th with an initial vale of $17 per share, and yesterday…

Novo focuses on new obesity therapy Semaglutide

Novo Nordisk reiterated last week, during a presentation to investors and analysts, the importance of its new investigational obesity therapy semaglutide for its future. Novo recently completed a Phase II clinical trial with semaglutide vs Saxenda vs Placebo, enrolling 1,000…